ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
November 22, 2021Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer... -
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
April 01, 2021Gracell Biotechnologies Inc. announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza for clinical manufacturing of Gracell's FasTCAR-enabled CAR-T cell product candidates in the U.S.
Pharma Sources Insight January 2025
